Eben Tessari - 16 Mar 2025 Form 4 Insider Report for Kiniksa Pharmaceuticals International, plc (KNSA)

Role
CHIEF OPERATING OFFICER
Signature
/s/ Madelyn Zeylikman, Attorney-in-Fact
Issuer symbol
KNSA
Transactions as of
16 Mar 2025
Net transactions value
-$13,046
Form type
4
Filing time
19 Mar 2025, 17:50:36 UTC
Previous filing
12 Mar 2025
Next filing
03 Apr 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KNSA Class A Ordinary Share Options Exercise +1,964 +2.6% 78,530 16 Mar 2025 Direct F1
transaction KNSA Class A Ordinary Share Tax liability $13,046 -577 -0.73% $22.61 77,953 16 Mar 2025 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KNSA Restricted Share Unit Options Exercise $0 -1,964 -100% $0.000000 0 16 Mar 2025 Class A Ordinary Share 1,964 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer.
F2 The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, March 16, 2021.